Keros Q3 net loss $53M; cash $530.7M; Phase 2 PAH trial fully enrolled

Keros Therapeutics, Inc.

2024-Q3 EPS reported -$3.88

Net loss of $53.0M in Q3 2024 vs $39.4M in Q3 2023; R&D expenses rose to $49.2M.
Cash and cash equivalents $530.7M as of Sep 30, 2024; ATM proceeds extend runway into Q3 2027.
Completed enrollment ahead of schedule in Phase 2 TROPOS trial (cibotercept) for pulmonary arterial hypertension.
Appointed Yung H. Chyung, M.D. as Chief Medical Officer effective Nov 1, 2024.
Expects clinical data updates from three assets over next nine months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.